The EBM portfolio dashboard specified in Appendix C of Evolve: The Operating Model AI Demands (Hodgson, 2026) is a practical tool for executive teams managing a portfolio of products in an environment where AI has changed both what is possible and what investment decisions require. It structures portfolio choices around four empirical measures drawn from the Evidence-Based Management framework (Scrum.org, 2024): what customers value now, what they could value in the future, how quickly the organisation can respond to both, and how well it has maintained the capacity to do so. These four measures — Current Value, Unrealised Value, Time to Market, and Ability to Innovate — do not replace financial analysis. They provide the evidence base that financial analysis requires to be meaningful at the product level.
In Brief
- Portfolio investment decisions made without empirical data on product outcomes produce two systematic failure modes: continued funding of products that customers have stopped valuing, and termination of products generating genuine value that resist financial measurement.
- The EBM portfolio dashboard structures decisions across four empirical measures — Current Value, Unrealised Value, Time to Market, and Ability to Innovate — making each decision defensible, consistent, and reversible.
- This page specifies what to collect, at what cadence, and what the evidence means for the four investment decisions available to a portfolio executive: persevere, pivot, pause, or stop.
Portfolio investment decisions made without empirical data on product outcomes consistently produce one of two failure modes. The first is continued investment in products that customers have stopped valuing, sustained by internal advocacy and sunk-cost reasoning rather than external evidence. The second is termination of products that are producing genuine customer outcomes but are difficult to measure in financial terms. The EBM portfolio dashboard is designed to prevent both, by specifying what data to collect, at what frequency, and what that data means for decisions about which products to fund, which to redirect, which to pause, and which to stop.
Portfolio investment decisions require consistent criteria applied to every product
The dashboard operates at the portfolio level, not the product level. Its purpose is to give an executive team the data to make consistent investment decisions across a set of products, applying the same criteria in the same way. Each product in the portfolio is assessed against all four value areas at a defined cadence. Assessments are not audits; they are structured conversations informed by data, designed to surface the evidence an executive needs to distinguish products performing as intended from those requiring a different approach.
The dashboard does not predict outcomes. It describes current state with enough fidelity to identify which direction the evidence points. A product generating strong Current Value with high Unrealised Value and improving Time to Market warrants continued or increased investment. A product with declining Current Value, low Unrealised Value, and deteriorating Ability to Innovate has produced all available signal that resources should be redirected. Chapter 10 of Evolve (Hodgson, 2026) sets out the investment decision logic that maps EBM data to portfolio choices. This page specifies how to collect that data and what to look for in the result.
Current Value
Current Value measures the worth the product is delivering to customers and stakeholders now. It answers a single question: given what the organisation is producing and delivering, how much genuine value are customers experiencing?
Data sources
Customer outcome data is the primary source. Net Promoter Score, customer satisfaction ratings, and direct customer feedback through structured channels all contribute. Usage depth matters as much as access frequency: task completion rates, feature adoption, and session duration on core workflows indicate whether customers are deriving value, not just logging in. Revenue and retention metrics apply where the product is commercial. For internal products, the equivalent measure is whether the product reduces cost or removes friction for its users, tracked through time-on-task data and error rates rather than satisfaction scores alone.
Employee satisfaction with the product team is a secondary indicator. Teams building products that are genuinely valued operate differently from those defending a product that has lost its reason for existence. High attrition, difficulty hiring into product roles, and poor engagement scores are often earlier signals of declining Current Value than the customer data itself.
Reporting cadence
Product teams review core customer satisfaction metrics monthly; the portfolio review aggregates them quarterly. Usage data is continuous, surfaced in a weekly team dashboard and summarised at the monthly product review. Revenue and retention data follows the finance function’s reporting cadence, typically monthly, and feeds into the quarterly EBM review rather than running as a separate conversation.
Interpretation
Current Value data warrants a persevere decision when satisfaction metrics are stable or improving and usage depth is increasing. It warrants investigation when satisfaction scores are stable but usage is declining; this combination indicates customers are not actively dissatisfied but are finding alternatives. It warrants a pivot or stop consideration when satisfaction is declining and usage is contracting simultaneously, particularly if that pattern has continued across two or more review periods without a corresponding change in product direction.
The investment implication of strong Current Value is retention of funding at current levels as a minimum. High Current Value combined with positive signals across the other three areas is the condition for an increase. Declining Current Value, absent a credible explanation tied to a deliberate product decision, is the primary driver of a stop recommendation.
Unrealised Value
Unrealised Value measures the potential future value the product could deliver if it fully met the needs of its intended customer base. It answers a different question from Current Value: how much of the available opportunity has this product captured, and how much remains?
Data sources
Market share data provides the clearest view of Unrealised Value for commercial products. The gap between current customer penetration and total addressable market is the most direct indicator of what remains to be captured. For internal products, the equivalent is the proportion of eligible users who have adopted the product at the level it was designed for. A product built for 5,000 users with 800 active users at intended depth has substantial Unrealised Value, provided those 4,200 non-users represent a genuine opportunity rather than a signal that the product is not fit for purpose.
Customer satisfaction gap analysis is the complementary source: the difference between what customers say they need and what the product currently provides. This data comes from customer interviews, feature request volumes and satisfaction scores by use case, and competitive intelligence showing what alternatives offer that the product does not.
Reporting cadence
Unrealised Value analysis is conducted quarterly as part of the portfolio review. It is not a continuous metric in the way Current Value is, because the market context it measures changes slowly enough that more frequent review produces noise rather than signal. The exception is competitive displacement: where a competitor has made a significant move that changes the opportunity available to the product, a triggered review outside the quarterly cadence is appropriate.
Interpretation
High Unrealised Value is not automatically an instruction to invest more. It is evidence of an opportunity, and the decision to pursue it depends on whether Time to Market and Ability to Innovate indicate the product team can realistically capture it. A product with high Unrealised Value but consistently poor Time to Market and declining Ability to Innovate needs structural change before any investment increase.
Declining Unrealised Value requires the most careful interpretation. If Unrealised Value is declining because the product is capturing its market — current penetration is increasing toward the ceiling — that is a positive signal. If it is declining because the ceiling itself is lower than originally estimated, or because the customer need has shifted, that is a stop signal. Distinguishing between the two requires the customer satisfaction gap data, not the market share data alone.
Time to Market
Time to Market measures the organisation’s ability to deliver new capabilities to customers quickly. It answers the question: how much time passes between identifying a customer need and putting a working response in customers’ hands?
Data sources
Cycle time is the primary measure: the elapsed time from work start to customer delivery. Lead time, which includes the time work spends waiting before it starts, provides a fuller picture and is more useful for identifying where in the system delays are being produced. Release frequency and deployment frequency indicate how regularly the team is delivering to production, which is the precondition for short cycle times.
Defect escape rate matters here because defects in production extend the effective time to market for the work that follows them. A team spending significant capacity on unplanned defect remediation has less capacity to respond to customer needs. Customer wait time, the elapsed time from when a customer identifies a need to when they receive a working solution, most directly reflects the customer experience of Time to Market.
Reporting cadence
Time to Market metrics are available continuously at the product team level and reviewed monthly at the product review. Portfolio-level review is quarterly, with trend data across at least three prior periods to distinguish a temporary variation from a systemic change in delivery performance.
Interpretation
When a product with stable or improving Current Value is also improving on Time to Market, the team is responding to customer needs effectively. The combination of improving Time to Market and declining Current Value is a different signal: the team is delivering faster, but not what customers need. This is the point at which to examine whether the product’s direction, not its delivery capability, is the source of the problem.
Deteriorating Time to Market in a product with high Unrealised Value is the pivot signal: the constraint on value capture is delivery speed, not market opportunity. The investment decision is to redesign the delivery system, not add features. Persistent, worsening Time to Market across multiple review periods, absent a clear structural cause, indicates a systemic problem in the delivery model that additional feature funding will not resolve.
Ability to Innovate
Ability to Innovate measures the organisation’s capacity to produce new capabilities that better serve customer needs, including needs the customer has not yet articulated. It answers the question: is the team able to respond to emerging opportunities, or is it constrained by the weight of what it has already built?
Data sources
Technical debt ratio is the primary indicator: the proportion of team capacity spent maintaining existing functionality versus building new capability. A team spending more than 30 to 40 per cent of capacity on maintenance, defect remediation, and technical remediation is signalling that its Ability to Innovate is being consumed by its past decisions. Innovation rate tracks the same dynamic from the output side; it measures the proportion of delivery that represents new capability rather than maintenance, compliance, or remediation work.
Unplanned work percentage, the proportion of team capacity consumed by urgent and unscheduled demands, is the leading indicator of trouble ahead. High unplanned work volume is the early warning that technical debt or operational fragility is beginning to dominate the system before it appears in cycle time or delivery rate. Employee capability development investment, measured as the proportion of time the team spends in deliberate learning and experimentation, completes the indicator set.
Reporting cadence
Ability to Innovate indicators are reviewed monthly at the product level and quarterly at the portfolio level. Technical debt ratio and innovation rate benefit from trend analysis over six to twelve months because they change slowly and short-term variation is not meaningful.
Interpretation
Declining Ability to Innovate in a product with high Current Value is the pause signal. The product is performing, but the team’s capacity to sustain that performance is being consumed. Continuing to invest in features without resolving the technical constraints will produce short-term delivery at the cost of medium-term capability. The correct response is to fund technical remediation before increasing feature investment.
Strong Ability to Innovate in a product with low Current Value warrants investigation rather than immediate action; the team has capacity, but it is not producing outcomes customers value. This is most often a product direction problem rather than a team capability problem, and the appropriate response is to examine the connection between what the team is building and what customers need.
The four value areas examined in sequence surface the portfolio decision
The four value areas are not independent. The interactions between them produce the most useful signals for portfolio investment decisions, and the quarterly review is designed to read them in sequence.
The sequence in which the four areas are examined matters because each one frames the next. Current Value is examined first because it establishes the foundation. A product with strong Current Value has earned the right to have its future examined. A product with declining Current Value is already facing a stop consideration, and the evidence from the other three areas determines whether that consideration is immediate or deferred pending a defined intervention.
Unrealised Value is examined second because it defines the opportunity ceiling. The investment question is whether the opportunity the product is addressing is large enough to justify continued investment at any level — not whether to invest at all. A product with declining Current Value and low Unrealised Value has no credible path to a different outcome without a fundamental change in what it is for.
Time to Market comes third: can the team actually reach the opportunity the data reveals? High Unrealised Value combined with poor Time to Market is a delivery system problem, not a product problem, and the investment decision must reflect that distinction. Funding product development in a team that cannot deliver at the speed the market requires produces output without outcomes.
Ability to Innovate is examined last, and it answers the question most executives defer: how long can current performance be sustained? A team with declining Ability to Innovate cannot sustain the delivery performance its current metrics show indefinitely. The quarterly review uses Ability to Innovate data to identify which products are on a trajectory toward delivery constraint before that constraint becomes visible in Current Value.
Tensions between areas are more informative than alignment. When all four areas are positive, the decision is straightforward: persevere, and review whether investment should increase. When areas are in tension, the pattern of that tension identifies the appropriate decision.
Strong Current Value combined with high Unrealised Value, poor Time to Market, and declining Ability to Innovate signals that the product has an audience and an opportunity but the delivery system is constraining both. The decision is to pause new feature investment and resolve the delivery system constraints before they produce a Current Value decline.
Declining Current Value combined with high Unrealised Value, strong Time to Market, and strong Ability to Innovate signals that the product can deliver and innovate, but is not currently meeting customer needs. The decision is to pivot; the team has the capability but the direction requires change.
Strong Current Value combined with declining Unrealised Value, strong Time to Market, and strong Ability to Innovate signals that the product is performing well but the opportunity is mature or shrinking. The decision is to sustain at current investment while directing the team’s delivery capability toward building what follows it.
Declining Current Value combined with low Unrealised Value, poor Time to Market, and declining Ability to Innovate means all four areas produce the same signal. The decision is to stop. Further investment has no credible path to a different outcome.
Worked example: a quarterly review across five products
The following example applies the EBM portfolio dashboard to a portfolio of five products at the quarterly review. Each product receives a decision: persevere, pivot, pause, or stop.
Product A — Customer Onboarding Portal
Current Value data is strong: NPS has increased from 34 to 47 over three quarters and task completion rate has improved from 61 to 79 per cent. Unrealised Value is moderate: market penetration sits at 63 per cent of eligible customers, and satisfaction gap analysis indicates that complex-case customers remain underserved. Time to Market is strong: cycle time has decreased from 18 days to 11 days over two quarters, and release frequency is fortnightly. Ability to Innovate is stable at 72 per cent innovation rate, with technical debt ratio holding at 21 per cent.
The primary signal is Current Value: the product is delivering measurably better outcomes and the delivery system is improving. The moderate Unrealised Value in the complex-case segment warrants a focused product direction conversation, but does not change the investment level. Decision: persevere.
Product B — Regulatory Reporting Module
Current Value has deteriorated significantly. Satisfaction scores have dropped from 58 to 39 over two quarters. Usage has contracted as teams develop manual workarounds for high-complexity reports rather than using the module. Unrealised Value analysis indicates the market need is fully served by three competing internal tools built independently in response to the module’s limitations; the opportunity ceiling has closed entirely, not merely contracted. Time to Market is poor: cycle time averages 34 days, with high defect escape rates consuming 40 per cent of team capacity. Ability to Innovate is critically low at 31 per cent innovation rate, with 58 per cent of capacity on maintenance and unplanned defect work.
All four areas produce the same signal, and the Unrealised Value finding is the definitive one: the opportunity this product was built to address is no longer available to it. Decision: stop. The investment funds team capacity that will produce more value applied to products with genuine opportunity.
Product C — AI-Assisted Case Management Tool
Current Value sits in the moderate range. Customer satisfaction is at 52 NPS, but usage depth is high among the 31 per cent of eligible users who have adopted the tool. Unrealised Value is substantial — 69 per cent of eligible users have not adopted the tool, and satisfaction gap analysis indicates the tool’s current capability addresses the primary user need effectively. Time to Market is the constraint: cycle time averages 29 days, release frequency is monthly, and the team’s primary bottleneck is the approval process for AI-generated outputs, which requires a manual review step that is not resourced to keep pace with delivery.
The Time to Market data identifies the decision. The product direction is correct — the capability is delivering genuine value to users who have adopted it, and the Unrealised Value is real. The constraint is the delivery system, specifically the manual review bottleneck. Decision: pivot. The investment focus shifts from feature development to redesigning the human-in-the-loop review process to increase throughput. Feature investment is paused pending resolution.
Product D — Mobile Field Inspection App
Current Value is stable. NPS is 61 and usage is broad across the eligible user base at 84 per cent adoption. Unrealised Value is limited — the product has captured its market effectively, and the remaining 16 per cent of non-users are in contexts where mobile access is genuinely unavailable. Time to Market is strong at nine-day average cycle time. Ability to Innovate has declined from 68 to 44 per cent innovation rate over three quarters, with unplanned work percentage increasing from 12 to 31 per cent. Technical debt ratio has reached 42 per cent.
Current Value confirms a performing product. The Ability to Innovate data identifies the risk: the technical constraints are consuming delivery capacity at a rate that will produce a Time to Market decline within one to two quarters if not addressed. Decision: pause. New feature investment is suspended for one quarter while the team reduces the technical debt. The pause is time-bounded: it is conditional on Ability to Innovate returning to above 60 per cent innovation rate before feature investment resumes.
Product E — Portfolio Analytics Platform
Current Value is strong and improving: NPS at 71, usage depth high across all user segments, and a measurable reduction in the time portfolio managers spend producing quarterly reviews: from 3.2 days to 0.8 days per review cycle. Unrealised Value is high — the platform currently serves the investment portfolio team but has been assessed as directly applicable to the program delivery and enterprise architecture functions, each representing a comparable adoption opportunity. Time to Market is strong at eight-day cycle time and weekly releases. Ability to Innovate is robust at 78 per cent innovation rate with technical debt ratio at 18 per cent.
All four areas are positive and the Unrealised Value finding indicates a material expansion opportunity (Hodgson, 2026). Decision: persevere with increased investment. The expansion to program delivery and enterprise architecture functions is approved. Team capacity increases by two senior engineers to support the platform’s extension to new user segments.
The dashboard makes portfolio investment decisions defensible, consistent, and reversible
Across these five products, the quarterly review produces two persevere decisions — Product A at current investment and Product E with an increase — one stop, one pivot, and one pause. Each decision is anchored to the value area that provides the primary evidence: Current Value drives the persevere for Product A; Unrealised Value drives the stop for Product B; Time to Market drives the pivot for Product C; Ability to Innovate drives the pause for Product D; and the convergence of all four positive signals, including a substantial Unrealised Value finding, drives the investment increase for Product E.
The dashboard does not make the decision. It produces the evidence that makes the decision defensible, consistent, and reversible. Portfolio investment choices made through this mechanism can be revisited when the data changes; decisions made on advocacy, precedent, or funding inertia have no equivalent mechanism for correction (Scrum.org, 2024).
What this means for portfolio executives
- Investment decisions anchored to advocacy — internal sponsorship, sunk-cost reasoning, funding inertia — have no mechanism for correction when the underlying evidence changes. The EBM dashboard provides that mechanism by separating evidence collection from the decision itself, making both independently auditable at the next quarterly review.
- The four value areas carry the most decision-relevant information in tension, not alignment. A product where all four areas are positive has an unambiguous answer. A product where areas conflict surfaces the specific constraint: product direction, delivery system, or technical capacity. The portfolio review is most valuable in those cases, not the straightforward ones.
- Time to Market and Ability to Innovate are leading indicators. Declining performance in either area will appear in Current Value within one to two review cycles if not addressed. Portfolio executives who act on leading indicators spend less on remediation than those who wait for Current Value to confirm the problem.
- A stop decision requires both declining Current Value and low Unrealised Value. A product with declining Current Value but high Unrealised Value is a pivot candidate, not a stop. Conflating the two produces premature termination of products that, with a change in direction, retain genuine opportunity.
- The quarterly cadence is what makes decisions reversible. A product paused with a defined condition for reinvestment — Ability to Innovate returning to above 60 per cent innovation rate, for instance — has a re-entry mechanism. A product stopped under portfolio pressure has none.
References
- Hodgson, M. (2026). Evolve: The Operating Model AI Demands. Zen Ex Machina.
- Scrum.org. (2024). Evidence-Based Management Guide. https://www.scrum.org/resources/evidence-based-management-guide
